The Food and Drug Administration (FDA) has approved Gilead Sciences’ Truvada, the first pharmaceutical drug to prevent the virus that causes AIDS.

Some of the senior members of Gilead Sciences include:

John C. Martin, Chairman and Chief Executive Officer, who served on the Centers for Disease
Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS and worked for competitors Bristol-Myers Squibb and Syntex Corporation.

Robin L. Washington, Senior Vice President and Chief Financial Officer who was a former accounting analyst for the Federal Reserve Bank of Chicago.

Kevin Young, Executive Vice President, Commercial Operations, who was appointed Commander of The British Empire for his service to the healthcare and pharmaceutical industries.

Margaret Hamburg, FDA commissioner, released a statement saying that the approval by the FDA “marks an important milestone in our fight against HIV.”

Marketed as a preventative for people who are at high risk of contracting HIV through sexual activies, Turvada is supported by public health advocates that believe this pill will slow
down the spread of HIV.

read full article http://www.activistpost.com/2012/07/...tive-pill.html